Misonix Incorporated Release: SonicOne Study Shows Improved Wound Healing In Patients With Peripheral Vascular Disease

FARMINGDALE, N.Y., Nov. 20, 2014 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications reported today that a SonicOne clinical paper was presented at the Canadian Association of Wound Care 20^th Annual Conference in Toronto, Ontario held October 30 - November 2, 2014.

The SonicOne is an innovative surgical device that allows clinicians to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne  establishes a new standard in wound debridement, an essential component in the wound healing process. Use of the SonicOne system provides controlled tissue removal, reduced healing times, minimal bleeding and a reduction of bioburden and biofilm.

In an abstract entitled, "The Effect of Low Frequency 22.5kHz Contact Ultrasound-assisted Debridement (LFCUD) on Lower Extremity Wounds in a Vascular Surgery Clinic:  A Pilot Study", Murphy, Houghton, Brandys and Rose concluded that LFCUD improved tissue quality and decreased Wound Surface Area in a complex patient population with peripheral vascular disease. These results achieved statistical significance.

"SonicOne was easy to use, comfortable for the patient and permitted grafted closure in a population often ineligible," said study lead Christine Murphy, a wound care nurse at The Ottawa Hospital in Ontario, Canada. "Our pilot study showed that LFCUD was a well-tolerated and convenient method of debridement because it could be administered by non-physician staff outside of the operating room and resulted in improved healing outcomes in the majority of cases involved."

The pilot study has evolved into a randomized controlled clinical trial that is currently underway at The Ottawa Hospital's Wound Healing Centre. The trial has enrolled 46 of 82 patients to date and is scheduled to complete enrollment in the spring of 2015.

"These are very exciting findings as the peripheral vascular diseased patient population in this study represents some of the most challenging wound cases to effectively bring to healing. SonicOne ultrasonic wound debridement continues to be highly regarded as a safe and effective means to improve wound healing, even in the complex patient," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contacts:

SOURCE Misonix, Inc.